MedTech & Diagnostics
Ge HealthCare Technologies Executive Compensation (FY25)
GEHC · Chicago, IL · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 11, 2026
349 figures on this page: 345 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
Peter Arduini, President and Chief Executive Officer, received $18,562,794 in total compensation for fiscal 2025, and Arduini's total was 4.7% lower than the $19,487,880 reported for fiscal 2024. Meanwhile, the disclosed chief executive pay ratio for fiscal 2025 is 241:1, against median employee compensation of $76,951. Separately, the say-on-pay proposal drew 96.4% of votes cast for or against in favor at the meeting held May 7, 2026 for fiscal 2025. The disclosed peer group includes Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company and Boston Scientific Corporation, among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Peter Arduini: $19,487,880 → $18,562,794 (4.7% lower)
Say-on-pay support: 94.7% → 96.4% (1.7 points higher)
CEO pay ratio: 267:1 → 241:1 (9.7% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Ge HealthCare Technologies' chief executive and what were they paid?
Peter Arduini, President and Chief Executive Officer, received $18,562,794 in total compensation for fiscal 2025. Arduini's total was 4.7% lower than the $19,487,880 reported for fiscal 2024.
What was Ge HealthCare Technologies' say-on-pay result?
The say-on-pay proposal drew 96.4% of votes cast for or against in favor at the meeting held May 7, 2026 for fiscal 2025.
Which companies are in Ge HealthCare Technologies' peer group?
The disclosed peer group includes Abbott Laboratories, Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company and Boston Scientific Corporation, among others.
What is Ge HealthCare Technologies' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 241:1, against median employee compensation of $76,951.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Peter Arduini President and CEO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Frank Jimenez General Counsel and Corporate Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Betty Larson Chief People Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Helmut Zodl Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jan Makela President & CEO, Imaging | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Peter Arduini President and CEO | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Taha Kass-Hout Chief Science and Technology Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
James Saccaro VP and CFO | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Frank Jimenez General Counsel and Corporate Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Peter Arduini President and CEO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Taha Kass-Hout Chief Science and Technology Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
James Saccaro VP and CFO | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Frank Jimenez General Counsel and Corporate Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Roland Rott President and CEO, Imaging | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Peter Arduini President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Taha Kass-Hout Chief Science and Technology Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
James Saccaro Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Frank Jimenez General Counsel and Corporate Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jeannette Bankes President and CEO, Patient Care Solutions | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Frank Jimenez | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Frank Jimenez | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| Frank Jimenez | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| James Saccaro | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| James Saccaro | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| James Saccaro | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jeannette Bankes | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jeannette Bankes | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jeannette Bankes | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| Jeannette Bankes | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Peter Arduini | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| Peter Arduini | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Peter Arduini | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Taha Kass-Hout | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Taha Kass-Hout | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| Taha Kass-Hout | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| James Saccaro | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/1/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| Option | ◇ | — | ◇ | 6/1/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 6/1/2033 | |
| Jeannette Bankes | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/15/2035 | |
| Frank Jimenez | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 2/1/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/1/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/1/2034 | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Taha Kass-Hout | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/1/2033 | |
| Option | ◇ | — | ◇ | 3/1/2034 | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| Option | ◇ | — | ◇ | 2/1/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Peter Arduini | Option | ◇ | — | ◇ | 3/1/2033 |
| Option | ◇ | — | ◇ | 3/1/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/1/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/1/2033 | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
H. Lawrence Culp, Jr | ◇ | ◇ | — | — | — | — | ◇ |
Risa Lavizzo-Mourey | ◇ | ◇ | — | — | — | — | ◇ |
Catherine Lesjak | ◇ | ◇ | — | — | — | — | ◇ |
William J. Stromberg | ◇ | ◇ | — | — | — | ◇ | ◇ |
Tomislav Mihaljevic | ◇ | ◇ | — | — | — | — | ◇ |
Phoebe L. Yang | ◇ | ◇ | — | — | — | — | ◇ |
Anne T. Madden | ◇ | ◇ | — | — | — | — | ◇ |
Rodney F. Hochman | ◇ | ◇ | — | — | — | — | ◇ |
Lloyd W. Howell, Jr | ◇ | ◇ | — | — | — | — | ◇ |
Peter J. Arduini and Kevin A. Lobo served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Abbott Laboratories ABT
- Agilent Technologies, Inc. A
- Baxter International Inc. BAX
- Becton, Dickinson and Company BDX
- Boston Scientific Corporation BSX
- Danaher Corporation DHR
- Edwards Lifesciences Corporation EW
- Hologic, Inc. HOLX
- Intuitive Surgical, Inc. ISRG
- Koninklijke Philips N.V. PHG
- Medtronic plc MDT
- Quest Diagnostics Incorporated DGX
- Siemens Healthineers AG symbol not shown
- Stryker Corporation SYK
- Thermo Fisher Scientific Inc. TMO
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 7, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 28, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 21, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 23, 2023 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Ge HealthCare Technologies disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Ge HealthCare Technologies sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
349 figures on this page: 345 cited to the filing that reported them, 4 calculated from figures it prints.
345 cited to the filing
4 calculated from the filing
Documents cited
- 0001932393-26-000034Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001932393-26-000021CEO Pay Ratio · Compensation Tables · Director Compensation · Director Compensation Table · and 3 more sections
- 0001932393-25-000032Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-25-017240Summary Compensation Table
- 0001628280-24-024926
- 0001932393-24-000022Compensation Tables · Summary Compensation Table
- 0001932393-23-000094
- 0001932393-23-000070Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Ge HealthCare Technologies executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/GEHC (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Ge HealthCare Technologies and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Ge HealthCare Technologies discloses
The companies named in GEHC's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}